ASKB-589

N/A

Report date: 2023/10/18 15:41:06

Base Information

Drug NameASKB-589
Drug Alias NameASKB-589
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CLDN18Antibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Aosaikang Pharmaceutical Co LtdAskGene Pharma Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Aosaikang Biomedical Co LtdAskGene Pharma IncJiangsu Aosaikang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A